ResMed CEO Michael Farrell sells $499k in stock By Investing.com todayheadline

Michael J. Farrell, the Chief Executive Officer of ResMed Inc . (NYSE:), recently sold 2,000 shares of the company’s common stock. The shares were sold at an average price of $249.665 each, totaling approximately $499,330. Following this transaction, the shares were held by the Lisette and Michael Farrell Foundation, with the CEO retaining dispositive power over the shares.

Additionally, Farrell engaged in a series of transactions involving gifts of shares. These included the transfer of 2,000 shares to the Lisette and Michael Farrell Family Foundation and another 2,000 shares from the Lisette and Michael Farrell Family Trust. Both of these transactions were conducted at no cost, and Farrell retains control over the transferred shares.

In a separate derivative transaction, Farrell acquired 33,036 stock options at an exercise price of $249.56 per share. These options will begin vesting on November 11, 2025, and will vest in one-third increments each year. Following these transactions, Farrell holds 455,472 shares of ResMed common stock directly.

In other recent news, ResMed Inc. has reported significant growth in its Q1 Fiscal Year 2025 Earnings Call, with an 11% increase in revenue and a 27% rise in operating profit. This growth has been attributed to strong demand for its sleep and respiratory health devices, notably the AirSense 10 and 11 platforms. Furthermore, the company announced the upcoming launch of the AirTouch N30i mask, which aims to improve patient adherence due to enhanced comfort.

In other developments, ResMed’s annual stockholders meeting resulted in the election of eleven directors and the ratification of KPMG LLP as the independent auditor for the fiscal year ending June 30, 2025. The shareholders also approved executive compensation. The company’s strategic focus includes expanding its core sleep health business and leveraging digital health, with the goal to empower over 500 million people with its health tech solutions by 2030.

Despite facing challenges such as increased inventory levels and persistent supply chain difficulties, ResMed is expected to maintain its growth trajectory through its focus on research and development, strategic acquisitions, and capital management. These recent developments underscore ResMed’s commitment to innovation and strategic growth in the health tech industry.

InvestingPro Insights

ResMed Inc. (NYSE:RMD) has demonstrated strong financial performance and market positioning, as reflected in recent InvestingPro data. The company’s market capitalization stands at $36.45 billion, underscoring its significant presence in the medical equipment industry. ResMed’s revenue growth of 9.88% over the last twelve months and 11.08% in the most recent quarter indicates robust demand for its products.

The company’s profitability is noteworthy, with a gross profit margin of 58.33% and an operating income margin of 30.84%. These figures suggest efficient cost management and strong pricing power. ResMed’s EBITDA growth of 24.39% further highlights its improving operational performance.

InvestingPro Tips reveal that ResMed has raised its dividend for 13 consecutive years, reflecting a commitment to shareholder returns. This is supported by the company’s dividend growth of 10.42% over the last twelve months. The stock’s impressive performance is evident in its 65.38% total return over the past year and its current trading price at 95.48% of its 52-week high.

While CEO Michael J. Farrell’s recent stock transactions might raise questions, it’s worth noting that ResMed operates with a moderate level of debt and its cash flows can sufficiently cover interest payments, indicating financial stability. The company’s high return over the last decade and analysts’ predictions of profitability this year further support a positive outlook.

For investors seeking a more comprehensive analysis, InvestingPro offers 15 additional tips for ResMed, providing deeper insights into the company’s financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.